Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity

Journal of Virology

Volumn 84, Issue 24, 2010, Pages 12691-12702

  Hong, David K ^a   Chang, Stella ^b   Botham, Crystal M ^a   Giffon, Thierry D ^a,c   Fairman, Jeffery ^b   Lewis, David B ^a  

^a STANFORD UNIVERSITY   (United States)

^b Juvaris BioTherapeutics Inc   (United States)

^c BN Immunotherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CATIONIC LIPID DNA COMPLEX; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2C; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; IMMUNOSTIMULATION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; DNA; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; LIPOSOMES; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; RNA VIRUSES;

EID: 78649395770     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00769-10     Document Type: Article

References (71)

1. Aigner, A. 2008. Cellular delivery in vivo of siRNA-based therapeutics. Curr. Pharm. Des. 14:3603-3619.
2. Assarsson, E., H. H. Bui, J. Sidney, Q. Zhang, J. Glenn, C. Oseroff, I. N. Mbawuike, J. Alexander, M. J. Newman, H. Grey, and A. Sette. 2008. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J. Virol. 82:12241-12251.
3. Atmar, R. L., and W. A. Keitel. 2009. Adjuvants for pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333:323-344.
4. Belz, G. T., W. Xie, and P. C. Doherty. 2001. Diversity of epitope and cytokine profiles for primary and secondary influenza A virus-specific CD8+ T cell responses. J. Immunol. 166:4627-4633.
5. Betts, M. R., and R. A. Koup. 2004. Detection of T-cell degranulation: CD107a and b. Methods Cell Biol. 75:497-512.
6. Boon, A. C., G. de Mutsert, D. van Baarle, D. J. Smith, A. S. Lapedes, R. A. Fouchier, K. Sintnicolaas, A. D. Osterhaus, and G. F. Rimmelzwaan. 2004. Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J. Immunol. 172:2453-2460.
7. Bragstad, K., L. P. Nielsen, and A. Fomsgaard. 2008. The evolution of human influenza A viruses from 1999 to 2006: a complete genome study. Virol. J. 5:40. (Pubitemid 351548819)
8. Brown, L. E., and A. Kelso. 2009. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol. Cell Biol. 87: 300-308.
9. Christensen, J. P., P. C. Doherty, K. C. Branum, and J. M. Riberdy. 2000. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory. J. Virol. 74:11690-11696.
10. Coutelier, J. P., J. T. van der Logt, F. W. Heessen, G. Warnier, and J. Van Snick. 1987. IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 165:64-69.
11. Crowe, J. E., Jr., E. C. Sannella, S. Pfeiffer, G. L. Zorn, A. Azimzadeh, R. Newman, G. G. Miller, and R. N. Pierson. 2003. CD154 regulates primate humoral immunity to influenza. Am. J. Transplant. 3:680-688.
12. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, M. Roederer, and R. A. Seder. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
13. Dienz, O., S. M. Eaton, J. P. Bond, W. Neveu, D. Moquin, R. Noubade, E. M. Briso, C. Charland, W. J. Leonard, G. Ciliberto, C. Teuscher, L. Haynes, and M. Rincon. 2009. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J. Exp. Med. 206:69-78.
14. Divekar, A. A., D. M. Zaiss, F. E. Lee, D. Liu, D. J. Topham, A. J. Sijts, and T. R. Mosmann. 2006. Protein vaccines induce uncommitted IL-2-secreting human and mouse CD4 T cells, whereas infections induce more IFN-gamma-secreting cells. J. Immunol. 176:1465-1473.
15. Doherty, P. C., S. J. Turner, R. G. Webby, and P. G. Thomas. 2006. Influenza and the challenge for immunology. Nat. Immunol. 7:449-455.
16. Ekiert, D. C., G. Bhabha, M. A. Elsliger, R. H. Friesen, M. Jongeneelen, M. Throsby, J. Goudsmit, and I. A. Wilson. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251.
17. Epstein, S. L., W. P. Kong, J. A. Misplon, C. Y. Lo, T. M. Tumpey, L. Xu, and G. J. Nabel. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23:5404-5410.
18. Fiers, W., M. De Filette, K. El Bakkouri, B. Schepens, K. Roose, M. Schotsaert, A. Birkett, and X. Saelens. 2009. M2e-based universal influenza A vaccine. Vaccine 27:6280-6283.
19. Finkelman, F. D., J. Holmes, I. M. Katona, J. F. Urban, Jr., M. P. Beckmann, L. S. Park, K. A. Schooley, R. L. Coffman, T. R. Mosmann, and W. E. Paul. 1990. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8:303-333.
20. Fiore, A. E., C. B. Bridges, and N. J. Cox. 2009. Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol. 333:43-82.
21. Forbes, E. K., C. Sander, E. O. Ronan, H. McShane, A. V. Hill, P. C. Beverley, and E. Z. Tchilian. 2008. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181:4955-4964.
22. Garcia, J. M., S. Pepin, N. Lagarde, E. S. Ma, F. R. Vogel, K. H. Chan, S. S. Chiu, and J. S. Peiris. 2009. Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One 4:e7918.
23. Gavin, A. L., K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. Nemazee. 2006. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314:1936-1938.
24. Geeraedts, F., L. Bungener, J. Pool, W. ter Veer, J. Wilschut, and A. Huckriede. 2008. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respir. Viruses 2:41-51.
25. Geeraedts, F., N. Goutagny, V. Hornung, M. Severa, A. de Haan, J. Pool, J. Wilschut, K. A. Fitzgerald, and A. Huckriede. 2008. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signaling. PLoS Pathog. 4:e1000138.
26. Gowen, B. B., J. Fairman, D. F. Smee, M. H. Wong, K. H. Jung, A. M. Pace, M. L. Heiner, K. W. Bailey, S. W. Dow, and R. W. Sidwell. 2006. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res. 69:165-172.
27. Grebe, K. M., J. W. Yewdell, and J. R. Bennink. 2008. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10:1024-1029.
28. He, X. S., T. H. Holmes, C. Zhang, K. Mahmood, G. W. Kemble, D. B. Lewis, C. L. Dekker, H. B. Greenberg, and A. M. Arvin. 2006. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 80:11756-11766.
29. Hehme, N., H. Engelmann, W. Kuenzel, E. Neumeier, and R. Saenger. 2004. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 103:163-171. (Pubitemid 38649075)
30. Heusser, C. H., C. L. Anderson, and H. M. Grey. 1977. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J. Exp. Med. 145:1316-1327.
31. Huber, V. C., J. M. Lynch, D. J. Bucher, J. Le, and D. W. Metzger. 2001. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166:7381-7388.
32. Huber, V. C., R. M. McKeon, M. N. Brackin, L. A. Miller, R. Keating, S. A. Brown, N. Makarova, D. R. Perez, G. H. Macdonald, and J. A. McCullers. 2006. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 13:981-990.
33. Jameson, J., J. Cruz, M. Terajima, and F. A. Ennis. 1999. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J. Immunol. 162:7578-7583.
34. Jegerlehner, A., P. Maurer, J. Bessa, H. J. Hinton, M. Kopf, and M. F. Bachmann. 2007. TLR9 signaling in B cells determines class switch recombination to IgG2a. J. Immunol. 178:2415-2420.
35. Kedzierska, K., N. L. La Gruta, S. J. Turner, and P. C. Doherty. 2006. Establishment and recall of CD8+ T-cell memory in a model of localized transient infection. Immunol. Rev. 211:133-145.
36. Kilbourne, E. D. 1969. Future influenza vaccines and the use of genetic recombinants. Bull. World Health Organ. 41:643-645.
37. Kilbourne, E. D., C. Smith, I. Brett, B. A. Pokorny, B. Johansson, and N. Cox. 2002. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc. Natl. Acad. Sci. U. S. A. 99:10748-10752.
38. Knossow, M., and J. J. Skehel. 2006. Variation and infectivity neutralization in influenza. Immunology 119:1-7.
39. Kunisaki, K. M., and E. N. Janoff. 2009. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis. 9:493-504.
40. La Gruta, N. L., S. J. Turner, and P. C. Doherty. 2004. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity. J. Immunol. 172:5553-5560.
41. Lay, M., B. Callejo, S. Chang, D. K. Hong, D. B. Lewis, T. D. Carroll, S. Matzinger, L. Fritts, C. J. Miller, J. F. Warner, L. Liang, and J. Fairman. 2009. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 27:3811-3820.
42. Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, and D. F. Tough. 2003. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4:1009-1015.
43. Lee, L. Y., D. L. A. Ha, C. Simmons, M. D. de Jong, N. V. Chau, R. Schumacher, Y. C. Peng, A. J. McMichael, J. J. Farrar, G. L. Smith, A. R. Townsend, B. A. Askonas, S. Rowland-Jones, and T. Dong. 2008. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J. Clin. Invest. 118:3478-3490.
44. Lewis, D. B. 2006. Avian flu to human influenza. Annu. Rev. Med. 57:139-154.
45. Liang, S., K. Mozdzanowska, G. Palladino, and W. Gerhard. 1994. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1653-1661.
46. Lu, X., L. E. Edwards, J. A. Desheva, D. C. Nguyen, A. Rekstin, I. Stephenson, K. Szretter, N. J. Cox, L. G. Rudenko, A. Klimov, and J. M. Katz. 2006. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24:6588-6593.
47. Markine-Goriaynoff, D., and J. P. Coutelier. 2002. Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J. Virol. 76:432-435.
48. Marrack, P., A. S. McKee, and M. W. Munks. 2009. Towards an understanding of the adjuvant action of aluminum. Nat. Rev. Immunol. 9:287-293.
49. Martin, R. M., J. L. Brady, and A. M. Lew. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J. Immunol. Methods 212:187-192.
50. Mbawuike, I. N., S. B. Dillion, S. G. Demuth, C. S. Jones, T. R. Cate, and R. B. Couch. 1994. Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein. Vaccine 12:1340-1348.
51. McCormack, S., A. Tilzey, A. Carmichael, F. Gotch, J. Kepple, A. Newberry, G. Jones, S. Lister, S. Beddows, R. Cheingsong, A. Rees, A. Babiker, J. Banatvala, C. Bruck, J. Darbyshire, D. Tyrrell, C. Van Hoecke, and J. Weber. 2000. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18: 1166-1177.
52. McMichael, A. J., F. M. Gotch, G. R. Noble, and P. A. Beare. 1983. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309:13-17.
53. Nelson, M. I., L. Edelman, D. J. Spiro, A. R. Boyne, J. Bera, R. Halpin, N. Sengamalay, E. Ghedin, M. A. Miller, L. Simonsen, C. Viboud, and E. C. Holmes. 2008. Molecular epidemiology of A/H3N2 and A/H1N1 influenza virus during a single epidemic season in the United States. PLoS Pathog. 4:e1000133.
54. Nguyen, H. H., F. W. van Ginkel, H. L. Vu, J. R. McGhee, and J. Mestecky. 2001. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J. Infect. Dis. 183:368-376.
55. Potter, C. W., and J. S. Oxford. 1979. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35:69-75.
56. Rao, N. M., and V. Gopal. 2006. Cell biological and biophysical aspects of lipid-mediated gene delivery. Biosci. Rep. 26:301-324.
57. Reed, L. J., and H. Muench. 1938. A simple method of estimating 50% endpoints. Am. J. Hyg. 27:493-497.
58. Rimmelzwaan, G. F., R. A. Fouchier, and A. D. Osterhaus. 2007. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18:529-536.
59. Rock, K. L., D. J. Farfan-Arribas, and L. Shen. 2010. Proteases in MHC class I presentation and cross-presentation. J. Immunol. 184:9-15.
60. Sarawar, S. R., M. Sangster, R. L. Coffman, and P. C. Doherty. 1994. Administration of anti-IFN-gamma antibody to beta 2-microglobulin-deficient mice delays influenza virus clearance but does not switch the response to a T helper cell 2 phenotype. J. Immunol. 153:1246-1253.
61. Stambas, J., C. Guillonneau, K. Kedzierska, J. D. Mintern, P. C. Doherty, and N. L. La Gruta. 2008. Killer T cells in influenza. Pharmacol. Ther. 120:186-196.
62. Sui, J., W. C. Hwang, S. Perez, G. Wei, D. Aird, L. M. Chen, E. Santelli, B. Stec, G. Cadwell, M. Ali, H. Wan, A. Murakami, A. Yammanuru, T. Han, N. J. Cox, L. A. Bankston, R. O. Donis, R. C. Liddington, and W. A. Marasco. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
63. Topham, D. J., and P. C. Doherty. 1998. Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells. J. Virol. 72:882-885.
64. Vugmeyster, Y., R. Glas, B. Perarnau, F. A. Lemonnier, H. Eisen, and H. Ploegh. 1998. Major histocompatibility complex (MHC) class I KbDb-/- deficient mice possess functional CD8+ T cells and natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 95:12492-12497.
65. Webster, R., N. Cox, and K. Stohr. 2002. WHO manual on animal influenza diagnosis and surveillance. WHO publication no. WHO/CDS/CSR/NCS/ 2002.5. Department of Communicable Disease Surveillance and Response, WHO Global Influenza Programme, World Health Organization, Geneva, Switzerland.
66. Wu, J., H. H. Fang, J. T. Chen, J. C. Zhou, Z. J. Feng, C. G. Li, Y. Z. Qiu, Y. Liu, M. Lu, L. Y. Liu, S. S. Dong, Q. Gao, X. M. Zhang, N. Wang, W. D. Yin, and X. P. Dong. 2009. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin. Infect. Dis. 48:1087-1095.
67. Yen, H. L., and J. S. Peiris. 2009. Mapping antibody epitopes of the avian H5N1 influenza virus. PLoS Med. 6:e1000064.
68. Zaks, K., M. Jordan, A. Guth, K. Sellins, R. Kedl, A. Izzo, C. Bosio, and S. Dow. 2006. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176:7335-7345. (Pubitemid 43849034)
69. Zambon, M. C. 2001. The pathogenesis of influenza in humans. Rev. Med. Virol. 11:227-241.
70. Zhong, W., P. A. Reche, C. C. Lai, B. Reinhold, and E. L. Reinherz. 2003. Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire. J. Biol. Chem. 278:45135-45144.
71. Zhu, N., D. Liggitt, Y. Liu, and R. Debs. 1993. Systemic gene expression after intravenous DNA delivery into adult mice. Science 261:209-211. (Pubitemid 23265397)